Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01246479 · ClinicalTrials.gov registry record · Phase 3
Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study
A Phase 3 study, sponsored by Valneva Austria.
- Completed
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
NCT01246479 is a Phase 3 study that has completed, run by Valneva Austria. The registered enrollment target is 23 participants.
The verdict
NCT01246479, a Phase 3 study, has completed, sponsored by Valneva Austria.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
Study Summary
The study investigates long-term immunity and safety of IC51 (IXIARO®, JESPECT®) in a pediatric population vaccinated in the parent study IC51-322.
Interventions
- PROCEDURE Blood draw
- BIOLOGICAL IC51 has given in the parent study IC51-322
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01246479
The ClinicalTrials.gov registry entry for NCT01246479 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Valneva Austria, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Blood draw is the first listed.
NCT01246479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01246479 about?
NCT01246479 is a clinical study titled "Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study". The study investigates long-term immunity and safety of IC51 (IXIARO®, JESPECT®) in a pediatric population vaccinated in the parent study IC51-322.
What is the current status of trial NCT01246479?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2010-10. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01246479?
The interventions under investigation include: Blood draw (PROCEDURE), IC51 has given in the parent study IC51-322 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01246479?
This trial is sponsored by Valneva Austria, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.